For start-ups and scale-ups, funding is the fuel for growth. But after a record-breaking year for insurtech investment, what can we expect to see in the investment space in 2022? Ruth Foxe Blader and Matthew Jones from venture capital investor Anthemis join Matthew to discuss the current financial markets and the opportunities that are attracting investors right now. Talking points include:

Assessing IPO performance and the investment appetite for insurtech
What Anthemis looks for from new companies and solutions
How new sources of data are creating new product opportunities
The growth of embedded insurance and what’s next
How to encourage entrepreneur diversity in insurtech

If you like what you're hearing, please leave us a review on whichever platform you use or contact Matthew Grant on LinkedIn.

Sign up to our newsletter for a fresh view on the world every Wednesday morning.

Continuing Professional Development - Learning Objectives

InsTech London is accredited by The Chartered Insurance Institute (CII). By listening to any InsTech London podcast or reading the accompanying transcript, you can claim up to 0.5 hours towards the CII member CPD scheme.

The Learning Objectives for this podcast are:

Define what an IPO is and how it is reflected in an investment's performance
Summarise some of the things an investor looks for in a new investment opportunity
Identify the developments in the insurance industry that are leading to new investment opportunities

If your organisation is a member of InsTech London and you would like to receive a quarterly summary of the CPD hours you have earned, visit the Episode 176 page of the InsTech London website or email cpd@instech.london to let us know you have listened to this podcast.

To help us measure the impact of the learning, we would be grateful if you would take a minute to complete a quick feedback survey.

Ruth Foxe Blader and Matthew Jones: Anthemis: What really matters - the investors’ view (176)

InsTech - insurance & innovation

Ruth Foxe Blader and Matthew Jones: Anthemis: What really matters - the investors’ view (176)